Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Neijssen J, Cardoso RMF, Chevalier KM, et al. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J Biol Chem. 2021. https://doi.org/10.1016/j.jbc.2021.100641.
2. Moores SL, Chiu ML, Bushey BS, et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 2016;76(13):3942–53.
3. Grugan KD, Dorn K, Jarantow SW, et al. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells. MAbs. 2017;9(1):114–26.
4. Janssen Biotech Inc. RYBREVANT (amivantamab-vmjw) injection, for intravenous use: US prescribing information. 2021. https://www.accessdata.fda.gov/. Accessed 11 Jun 2021.
5. US Food & Drug Administration. FDA approves first targeted therapy for subset of non-small cell lung cancer [media release]. https://www.fda.gov/. 21 May 2021.
Cited by
88 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献